VANCOUVER, British Columbia, Dec. 22, 2017 /PRNewswire/ — Lifestyle Delivery Systems Inc. (CSE: LDS), (OTCQB: LDSYF) and (Frankfurt: LD6, WKN: A14XHT) (“LDS” or the “Company”) announces that on December 21, 2017, the Manufactured Cannabis Safety Branch of the California Department of Public Health has issued CSPA Group, Inc. (“CSPA”) a Temporary Category M Type 7 Manufacturing with Volatile Solvents License which will be effective January 1, 2018 through April 30, 2018. During this time, the California Department of Public Health will review CSPA’s application and corresponding municipal permits and documentation for a permanent license.

Brad Eckenweiler, CEO of LDS, stated, “There are milestones and then there are milestones. This license marks the beginning of the most significant milestone yet in the development of the CannaStrips^TM project. On January 1, 2018 for the first time the LDS CannaStrips^TM technology with the CSPA Group Inc. licensee and LDS Scientific Inc. consulting will be producing a product for patients that is safe, free of contaminates, with accurate dosage, delivering consistent results and licensed by the State of California.” The CSPA Group, Inc. and the LDS Scientific team have been given the next ten days off as holiday reward for all their hard work and to rest up for the month ahead. Only minimal staff and our armed security will be at the facility until January 1, 2018, at which time the facility is expected to run two production shifts per day. We would like to wish every one of our shareholders and supporters a joyous carefree holiday and prosperous New Year.

About Lifestyle Delivery Systems Inc.

The Company’s technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to smoking, but also a new way to accurately meter the dosage and assure the purity of the product. In addition, with the entering into its management services agreements with NHMC, Inc. and CSPA Group, Inc., the Company has begun its direct involvement in the growing of medicinal ingredients for, and the manufacturing of, its products.  From seed to sale, the Company’s products and ingredients will be tested for quality and composition throughout the formulation and production processes, resulting in a delivery system that is safe, consistent and effective.

On behalf of the board of directors of Lifestyle Delivery Systems Inc.
Brad Eckenweiler, CEO & Director

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970.  Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, The Company undertakes no obligation to publicly update or revise forward-looking information.